Literature DB >> 1540383

In vitro tumor necrosis factor-alpha secretion by monocytes from patients with cystic fibrosis.

J S Elborn1, D Norman, F M Delamere, D J Shale.   

Abstract

Immunoreactive tumor necrosis factor-alpha (TNF-alpha) concentration is increased in plasma from patients with cystic fibrosis and chronic Pseudomonas aeruginosa pulmonary infection. To determine if circulating monocytes could be the source of plasma TNF-alpha, we determined in vitro basal and endotoxin-stimulated TNF-alpha secretion by monocytes. In 10 adult patients studied at the time of a symptomatic respiratory exacerbation, basal secretion of TNF-alpha was significantly less than that for 10 matched healthy controls (median 265 pg/micrograms DNA, nonparametric 95% confidence interval 193 to 463 pg/micrograms DNA versus 575, 298 to 923 pg/micrograms DNA; P less than 0.006), although both groups responded equally effectively to added Escherichia coli endotoxin at greater than or equal to 25 ng/ml. In six patients and six matched controls, monocyte culture was repeated after completion of 2 wk anti-pseudomonal antibiotic treatment in the patients. The reduced basal TNF-alpha secretion in the patients had reversed and was not significantly different to that of controls. This effect mirrored a significant reduction in plasma immunoreactive TNF-alpha in these patients (mean +/- SD, 258 +/- 59.3 pg/ml pretreatment versus 133 +/- 47.8 pg/ml post-treatment; P less than 0.05). These findings suggest that a reversible downregulation of TNF-alpha secretion occurred at the time of a symptomatic respiratory deterioration in the presence of chronic P. aeruginosa infection. This may represent a physiologic regulatory mechanism to maintain a local inflammatory response to chronic pulmonary infection in cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1540383     DOI: 10.1165/ajrcmb/6.2.207

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  8 in total

1.  Tumour necrosis factor alpha in severe congestive cardiac failure.

Authors:  D P Dutka; J S Elborn; F Delamere; D J Shale; G K Morris
Journal:  Br Heart J       Date:  1993-08

Review 2.  Cystic Fibrosis Lung Immunity: The Role of the Macrophage.

Authors:  Emanuela M Bruscia; Tracey L Bonfield
Journal:  J Innate Immun       Date:  2016-06-24       Impact factor: 7.349

Review 3.  Sputum biomarkers of inflammation in cystic fibrosis lung disease.

Authors:  Scott D Sagel; James F Chmiel; Michael W Konstan
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

4.  Immune monitoring of patients with septic shock by measurement of intraleukocyte cytokines.

Authors:  Thierry Fumeaux; Julien Dufour; Sabine Stern; Jérôme Pugin
Journal:  Intensive Care Med       Date:  2004-09-11       Impact factor: 17.440

5.  Metabolic and respiratory consequences of a glucose load in a hypoxic patient with cystic fibrosis.

Authors:  J S Elborn; T Jagoe; D J Shale
Journal:  Ulster Med J       Date:  1992-10

Review 6.  CFTR activity and mitochondrial function.

Authors:  Angel Gabriel Valdivieso; Tomás A Santa-Coloma
Journal:  Redox Biol       Date:  2013-02-05       Impact factor: 11.799

7.  Altered iron metabolism in cystic fibrosis macrophages: the impact of CFTR modulators and implications for Pseudomonas aeruginosa survival.

Authors:  H F Hazlett; T H Hampton; D S Aridgides; D A Armstrong; J A Dessaint; D L Mellinger; A B Nymon; A Ashare
Journal:  Sci Rep       Date:  2020-07-02       Impact factor: 4.379

8.  Monocytes from cystic fibrosis patients are locked in an LPS tolerance state: down-regulation of TREM-1 as putative underlying mechanism.

Authors:  Carlos del Fresno; Vanesa Gómez-Piña; Vanesa Lores; Alessandra Soares-Schanoski; Irene Fernández-Ruiz; Blas Rojo; Rodolfo Alvarez-Sala; Ernesto Caballero-Garrido; Felipe García; Tania Veliz; Francisco Arnalich; Pablo Fuentes-Prior; Francisco García-Río; Eduardo López-Collazo
Journal:  PLoS One       Date:  2008-07-16       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.